ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Nivolumab

Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.

Drug pageNivolumab: every studyMany companies study it; this page follows only the 145 they lead. All 1,032 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 2015145 company-led studies, 14 open or runningNext primary completion: Feb 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only12410 open or runningphase 4since Nov 2, 2015Feb 27, 2007Feb 5, 2027phase 2 · NCT06946797
Ono Pharmaceutical144 open or runningphase 3since Oct 9, 2014Jan 26, 2009Dec 31, 2027phase 2 · NCT04566380
Pfizerits history only20 open or runningphase 2since Oct 7, 2015Oct 7, 2015none ahead
Ella Therapeuticsits history only10 open or runningphase 2since Aug 13, 2020Aug 13, 2020none ahead
ExcellaBioits history only10 open or runningphase 2since Oct 20, 2017Oct 20, 2017none ahead
Nilogen Oncosystemsits history only10 open or runningearly phase 1since Dec 3, 2017Dec 3, 2017none ahead
Rampart Healthits history only10 open or runningphase 2since Aug 9, 2019Aug 9, 2019none ahead
USWM CTits history only10 open or runningphase 2since Oct 26, 2022Oct 26, 2022none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics, Medarex, Parexel, Astellas Pharma, Akamis Bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ono Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 26, 2009First study: phase 1 study in Malignant Solid TumorFirst studyNCT00836888 · 17 enrolled · Japan
  2. Jun 18, 2014Phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)NCT02175017 · 104 enrolled · Korea, Republic of
  3. Sep 30, 20142 phase 1 studies in Advanced Solid TumorsNCT02261298, NCT02261285
  4. Oct 9, 2014Phase 3 study in Stomach NeoplasmsNCT02267343 · 493 enrolled · Japan, Korea, Republic of, Taiwan
  5. Sep 30, 2015Phase 3 study in Esophageal NeoplasmsNCT02569242 · 419 enrolled · United States, Denmark, Germany and more
  6. Oct 20, 2015Phase 2 study in Advanced Non-small Cell Lung CancerNCT02582125 · 53 enrolled · Taiwan
  7. Mar 29, 2016Phase 3 study in Stomach NeoplasmsNCT02746796 · 680 enrolled · Japan, Korea, Republic of, Taiwan
  8. Dec 27, 2016Phase 3 study in Stomach NeoplasmsNCT03006705 · 800 enrolled · China, Japan, Korea, Republic of and more
  9. Apr 12, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungNCT03117049 · 550 enrolled · Japan, Korea, Republic of, Taiwan
  10. Sep 22, 2020Phase 2 study in Pan-tumorNCT04566380 · 70 planned · Japan, South Korea, Taiwan
  11. Oct 6, 2021Phase 3 study in Stomach NeoplasmsNCT05144854 · 626 enrolled · Japan, South Korea, Taiwan
  12. Sep 30, 2024Phase 2 study in Rhabdoid TumorNCT06622941 · 23 planned · Japan
  13. Apr 13, 2025Phase 2 study in Richter's TransformationNCT06936943 · 14 planned · Japan
  14. Oct 14, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 2 · +12 months · NCT04566380

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Pan-tumorNCT04566380
  2. Jan 31, 2029Primary completion: phase 2 study in Rhabdoid TumorNCT06622941
  3. Jul 31, 2029Primary completion: phase 2 study in Richter's TransformationNCT06936943

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 14 Ono Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06936943Richter's Transformation · Japan2RecruitingJul 31, 202914
NCT06622941Rhabdoid Tumor · Japan2RecruitingJan 31, 202923
NCT05144854Stomach Neoplasms · Japan, South Korea, Taiwan3Active, not recruitingOct 20, 2025626
NCT04566380Pan-tumor · Japan, South Korea, Taiwan2RecruitingDec 31, 202770
NCT03117049Carcinoma, Non-Small-Cell Lung · Japan, Korea, Republic of, Taiwan3CompletedFeb 10, 2020550
NCT03006705Stomach Neoplasms · China, Japan, Korea, Republic of and more3CompletedAug 17, 2022800
NCT02746796Stomach Neoplasms · Japan, Korea, Republic of, Taiwan3CompletedJan 2020680
NCT02582125Advanced Non-small Cell Lung Cancer · Taiwan2CompletedJan 4, 202153
NCT02569242Esophageal Neoplasms · United States, Denmark, Germany and more3CompletedOct 23, 2020419
NCT02267343Stomach Neoplasms · Japan, Korea, Republic of, Taiwan3CompletedAug 2016493
NCT02261298Advanced Solid Tumors · Korea, Republic of1CompletedJun 201518
NCT02261285Advanced Solid Tumors · Korea, Republic of1CompletedDec 201418
NCT02175017Advanced Non-small Cell Lung Cancer (NSCLC) · Korea, Republic of2CompletedNov 2015104
NCT00836888Malignant Solid Tumor · Japan1CompletedSep 201017

How it is read

Names in the registry

  • “Nivolumab”, 115 entries
  • “nivolumab”, 18 entries
  • “ONO-4538”, 13 entries
  • “BMS-936558 (MDX-1106)”, 5 entries
  • “Nivolumab + Relatlimab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.